<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672111</url>
  </required_header>
  <id_info>
    <org_study_id>HS-14-499</org_study_id>
    <nct_id>NCT02672111</nct_id>
  </id_info>
  <brief_title>Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder</brief_title>
  <official_title>An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braeburn Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braeburn Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label multi-center, 12-month safety study, consistent with standard practice for
      long-term safety studies. This one year safety study will utilize CAM2038 q1w (once weekly)
      and q4w (once monthly) and will have 3 phases: Screening, Treatment, and Follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label multi-center, 12-month safety study, consistent with standard practice for
      long-term safety studies. This one year safety study will utilize CAM2038 q1w (once weekly)
      and q4w (once monthly) and will have 3 phases: Screening, Treatment, and Follow-up.

      Patients who are currently taking sublingual (SL) BPN (weekly or monthly prescription visits)
      or individuals who are actively seeking BPN treatment but who have not yet begun a treatment
      regimen, may be eligible for the study.

      Following Screening, qualified subjects meeting inclusion criteria and not meeting exclusion
      criteria will be initiated on either CAM2038 q1w or q4w, based on their current treatment
      status (qualified subjects currently on SL BPN or seeking BPN treatment). Qualified subjects
      will be initiated or transitioned to CAM2038 q1w or q4w as follows:

      Initiation of BPN treatment - initiate with CAM2038 q1w Currently receiving SL BPN treatments
      - transfer to corresponding CAM2038 q1w or q4w dose
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of CAM2038 products in 100 adult outpatients with opioid use disorder via safety assessments.</measure>
    <time_frame>12 months</time_frame>
    <description>Safety Assessments: Adverse events (AEs) and serious adverse events (SAEs); Clinical laboratory tests; Electrocardiogram (ECG); Vital signs; Physical and injection site examinations; Concomitant medications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate efficacy of CAM2038 through several efficacy parameters, including urine toxicology, signs and symptoms of withdrawal and cravings in 100 adult outpatients with opioid use disorder.</measure>
    <time_frame>12 months (48 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">228</enrollment>
  <condition>Opioid Use Disorder</condition>
  <arm_group>
    <arm_group_label>CAM2038 (buprenorphine FluidCrystal®)q1w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAM2038 q1w(buprenorphine FluidCrystal®) : SC injection depot for once weekly administration) (50 mg/mL) at doses of 8, 16, 24 and 32 mg (buprenorphine base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAM2038(buprenorphine FluidCrystal®) q4w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAM2038 q4w ( buprenorphine FluidCrystal®): SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (buprenorphine base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)</intervention_name>
    <arm_group_label>CAM2038 (buprenorphine FluidCrystal®)q1w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAM2038 (buprenorphine FluidCrystal® once-monthly injection depot)</intervention_name>
    <arm_group_label>CAM2038(buprenorphine FluidCrystal®) q4w</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must provide written informed consent prior to the conduct of any
             study-related procedures.

          2. Male or female, 18-65 years of age, inclusive. (Taiwan: 20-65 years of age, inclusive)

          3. Female subjects of childbearing potential must be willing to use a highly effective
             method of contraception during the entire study (Screening Visit to Follow-Up Visit)
             (Section 9.1.6).

          4. Current diagnosis of moderate or severe opioid use disorder (DSM-V) or past medical
             history of opioid use disorder currently being treated with SL BPN.

          5. Considered by the Investigator to be a good candidate for BPN treatment, based on
             medical and psychosocial history.

          6. Subjects must meet one of the following criteria for BPN treatment history:

               -  Voluntarily seeking treatment for opioid use disorder (not currently on BPN
                  treatment for at least last 60 days but seeking BPN treatment), or;

               -  Currently on SL BPN treatment.

        Exclusion Criteria:

          1. Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS).

          2. Current diagnosis of chronic pain requiring opioids for treatment.

          3. Current DSM-V diagnosis for moderate to severe substance use disorder (including
             alcohol) other than opioids, caffeine or nicotine and currently being treated as the
             primary substance use disorder.

          4. Recent history of or current evidence of suicidal ideation or active suicidal behavior
             as based on the Columbia Suicide Severity Rating Scale (C-SSRS) (&quot;Yes&quot; responses to
             questions 4 or 5).

          5. Pregnant or lactating or planning to become pregnant during the study.

          6. Hypersensitivity or allergy to naloxone (only for subjects receiving the SL BPX test
             dose), BPN or excipients of CAM2038.

          7. Requires chronic use of agents that are strong inhibitors or inducers of cytochrome
             P450 3A4 (CYP 3A4) such as some azole antifungals (e.g., ketoconazole), macrolide
             antibiotics (e.g., clarithromycin), or protease inhibitors (e.g., ritonavir,
             indinavir, and saquinavir).

          8. Hepatitis, unless under stable treatment, at the discretion of the Investigator.

          9. Any pending legal action that could prohibit participation or compliance in the study.

         10. Exposure to any investigational drug within the 4 weeks prior to Screening.

         11. Aspartate aminotransferase (AST) levels ≥3 X the upper limit of normal, alanine
             aminotransferase (ALT), levels ≥ 3 X the upper limit of normal, total bilirubin ≥ 1.5
             X the upper limit of normal, or creatinine ≥ 1.5 X upper limit of normal on the
             Screening laboratory assessments, or other clinically significant laboratory
             abnormalities, which in the opinion of the Investigator may prevent the subject from
             safely participating in study.

         12. Participants with a history of risk factors of Torsades de Pointes (e.g., heart
             failure, hypokalemia, family history of Long QT Syndrome) or an ECG demonstrating a
             Fridericia's corrected QT interval (QTcF) &gt;450 msec in males and QTcF &gt; 470 in females
             at screening.

         13. Significant symptoms, medical conditions, or other circumstances which, in the opinion
             of the Investigator, would preclude compliance with the protocol, adequate cooperation
             in the study or obtaining informed consent, or may prevent the subject from safely
             participating in study. This includes, but is not limited to, subjects with attention
             deficit hyperactivity disorder receiving central stimulants (e.g. methylphenidate or
             other central stimulants), as well as subjects with severe respiratory insufficiency,
             respiratory depression, airway obstruction, gastrointestinal motility disorders,
             severe hepatic insufficiency, planned surgery and prior treatment with monoamine
             oxidase inhibitors.

         14. Is an employee of the Investigator or the trial site, with direct involvement in the
             proposed trial or other studies under the direction of the Investigator or trial site,
             or is a family member of an employee or of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Braeburn Pharmaceuticals</last_name>
  </overall_official>
  <location>
    <facility>
      <name>Parkway Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haleyville Clinical Research LLC</name>
      <address>
        <city>Haleyville</city>
        <state>Alabama</state>
        <zip>35565</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boyett Health Services Inc</name>
      <address>
        <city>Hamilton</city>
        <state>Alabama</state>
        <zip>35570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Vijapura and Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TRY Research</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanley Street Treatment and Resources Inc</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellness and Research Center</name>
      <address>
        <city>Belvidere</city>
        <state>New Jersey</state>
        <zip>07823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Research</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STARS/Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frost Medical Group, LLC</name>
      <address>
        <city>Conshohocken</city>
        <state>Pennsylvania</state>
        <zip>19428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown Nsw</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Eastern Sydney Local Health District (SESLHD)</name>
      <address>
        <city>New Surrey Hills Surry Hills</city>
        <zip>NSW 2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Community Health Services</name>
      <address>
        <city>Newcastle</city>
        <zip>NSW 2300</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug &amp; Alcohol Services SA Drug and Alcohol Services</name>
      <address>
        <city>Norwood</city>
        <zip>5070</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Misbrugsbehandling</name>
      <address>
        <city>Sumatravej 3</city>
        <state>Aarhus</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behandlingscenter Odense</name>
      <address>
        <city>Grønlandsgade 13 A</city>
        <state>Odense</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Schnaitmann/Schaffert Salzstrasse</name>
      <address>
        <city>Baden-Wurttemberg</city>
        <state>Heilbronn</state>
        <zip>74076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studikum - Zentrum fur Klinische Studien im Praxiszentrum Friedrichsplatz</name>
      <address>
        <city>Friedrichsplatz 2-3</city>
        <state>Kassel</state>
        <zip>34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fur Abhangiges Verhalten und Suchtmedizin Zentralinstitut</name>
      <address>
        <city>Baden-Wurttemberg Mannheim</city>
        <state>Mannheim</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychosoziale Begleitung - Praxis Boniakowski</name>
      <address>
        <city>Koenigswiesenweg 21</city>
        <state>Regensburg</state>
        <zip>93051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft</name>
      <address>
        <city>Schwabstrasse 59</city>
        <state>Stuttgart</state>
        <zip>70197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XVI. Kerület Kertvárosi Egészségügyi Szolgálata, Addiktológia</name>
      <address>
        <city>Gábor</city>
        <state>Budapest</state>
        <zip>1165</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinexpert Kft</name>
      <address>
        <city>Kaszasdulo u. 5.</city>
        <state>Budapest</state>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metadonsektionen</name>
      <address>
        <city>Beroendecentrum Tantogatan 8</city>
        <state>Stockholm</state>
        <zip>118 67</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrallasarettet Vasteras</name>
      <address>
        <city>Stockholmsvägen</city>
        <state>Västerås</state>
        <zip>72189</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospita</name>
      <address>
        <city>North District</city>
        <state>Taichung</state>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinan Psychiatric Center, Ministry of Health and Welfa</name>
      <address>
        <city>Jen-Te Hsien</city>
        <state>Tainan County</state>
        <zip>717</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei City Hospital</name>
      <address>
        <city>Datong District</city>
        <state>Taipei</state>
        <zip>103</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackberry Centre Blackberry Hill Hospital</name>
      <address>
        <city>Fishponds</city>
        <state>Bristol</state>
        <zip>BS16 2EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Tayside</name>
      <address>
        <city>DD at Ninewells Hospital and Medical School</city>
        <state>Dundee</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lambeth Drug and Alcohol Service Lorraine Hewitt House</name>
      <address>
        <city>Brighton Terrace</city>
        <state>London</state>
        <zip>SW9 8DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hellesdon Hospital The Weavers Centre</name>
      <address>
        <city>Hellesdon</city>
        <state>Norwich</state>
        <zip>NR6 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

